LC/MS/MS를 이용한 가바펜틴 300 mg 캡슐의 성인 지원자에 대한 생물학적 동등성 및 약물동태 연구

초록

Gabapentin, 1-(aminomethyl-1-cyclohexyl)acetic acid, is a new antiepileptic drug related to γ-aminobutyric acid(GABA) currently being introduced in therapy worldwide. The bioavailability and pharmacokinetics of gabapentin capsules were examined in 22 volunteers who received a single oral dose in the fasting state by randomized balanced 2x2 crossover design. After dosing, blood samples were collected for a period of 24 hours and analyzed by liquid chromatographytandem mass spectrometry (LC/MS/MS). Time course of plasma gabapentin concentration was analyzed with non-compartmental and compartmental approaches. WinNonlin®, the kinetic computer program, was used for compartmental analysis. One compartment model with first-order input, first-order output with no lag time and weighting by 1/(predicted y)2 was chosen as the most appropriate pharmacokinetic model for the volunteers. The major pharmacokinetic parameters (AUC0-24hr, AUCinf, Cmax and Tmax) and other parameters (Ka, Kel, Vd/F and Cl/F) of Gapentin TM (test drug) and Neurontin TM (reference drug) were estimated by non-compartmental analysis and compartmental analysis. The 90% confidence intervals of mean difference of logarithmic transformed AUC0-24hr and Cmax were log(0.9106)~log(1.1254) and log(0.8521)~log(1.0505), respectively. It shows that the bioavailability of the test drug is equivalent with that of the reference drug. There was no statistically significant difference between the two drugs in all pharmacokinetic parameters.

키워드